These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

382 related items for PubMed ID: 23146479

  • 1. Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation.
    Díaz-Molina B, Tavira B, Lambert JL, Bernardo MJ, Alvarez V, Coto E.
    Transplant Proc; 2012 Nov; 44(9):2635-8. PubMed ID: 23146479
    [Abstract] [Full Text] [Related]

  • 2. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients.
    Cho JH, Yoon YD, Park JY, Song EJ, Choi JY, Yoon SH, Park SH, Kim YL, Kim CD.
    Transplant Proc; 2012 Jan; 44(1):109-14. PubMed ID: 22310591
    [Abstract] [Full Text] [Related]

  • 3. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
    Elens L, Bouamar R, Hesselink DA, Haufroid V, van der Heiden IP, van Gelder T, van Schaik RH.
    Clin Chem; 2011 Nov; 57(11):1574-83. PubMed ID: 21903774
    [Abstract] [Full Text] [Related]

  • 4. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
    Shi Y, Li Y, Tang J, Zhang J, Zou Y, Cai B, Wang L.
    Gene; 2013 Jan 10; 512(2):226-31. PubMed ID: 23107770
    [Abstract] [Full Text] [Related]

  • 5. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
    Staatz CE, Goodman LK, Tett SE.
    Clin Pharmacokinet; 2010 Mar 10; 49(3):141-75. PubMed ID: 20170205
    [Abstract] [Full Text] [Related]

  • 6. Association of CYP3A4-392A/G, CYP3A5-6986A/G, and ABCB1-3435C/T Polymorphisms with Tacrolimus Dose, Serum Concentration, and Biochemical Parameters in Mexican Patients with Kidney Transplant.
    Alatorre-Moreno EV, Saldaña-Cruz AM, Pérez-Guerrero EE, Morán-Moguel MC, Contreras-Haro B, López-de La Mora DA, Dávalos-Rodríguez IP, Marín-Medina A, Rivera-Cameras A, Balderas-Peña LA, Gómez-Ramos JJ, Cortés-Sanabria L, Salazar-Páramo M.
    Genes (Basel); 2024 Apr 16; 15(4):. PubMed ID: 38674430
    [Abstract] [Full Text] [Related]

  • 7. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
    Jun KR, Lee W, Jang MS, Chun S, Song GW, Park KT, Lee SG, Han DJ, Kang C, Cho DY, Kim JQ, Min WK.
    Transplantation; 2009 Apr 27; 87(8):1225-31. PubMed ID: 19384171
    [Abstract] [Full Text] [Related]

  • 8. Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients.
    Genvigir FD, Salgado PC, Felipe CR, Luo EY, Alves C, Cerda A, Tedesco-Silva H, Medina-Pestana JO, Oliveira N, Rodrigues AC, Doi SQ, Hirata MH, Hirata RD.
    Pharmacogenet Genomics; 2016 Oct 27; 26(10):462-72. PubMed ID: 27434656
    [Abstract] [Full Text] [Related]

  • 9. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation.
    Gervasini G, Garcia M, Macias RM, Cubero JJ, Caravaca F, Benitez J.
    Transpl Int; 2012 Apr 27; 25(4):471-80. PubMed ID: 22369694
    [Abstract] [Full Text] [Related]

  • 10. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.
    Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y.
    Clin Pharmacol Ther; 2007 Dec 27; 82(6):711-25. PubMed ID: 17495880
    [Abstract] [Full Text] [Related]

  • 11. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
    Shi XJ, Geng F, Jiao Z, Cui XY, Qiu XY, Zhong MK.
    J Clin Pharm Ther; 2011 Oct 27; 36(5):614-24. PubMed ID: 21916909
    [Abstract] [Full Text] [Related]

  • 12. CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation.
    Hu R, Barratt DT, Coller JK, Sallustio BC, Somogyi AA.
    Basic Clin Pharmacol Toxicol; 2018 Sep 27; 123(3):320-326. PubMed ID: 29603629
    [Abstract] [Full Text] [Related]

  • 13. Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation.
    Turolo S, Tirelli AS, Ferraresso M, Ghio L, Belingheri M, Groppali E, Torresani E, Edefonti A.
    Pharmacol Rep; 2010 Sep 27; 62(6):1159-69. PubMed ID: 21273673
    [Abstract] [Full Text] [Related]

  • 14. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE, Goodman LK, Tett SE.
    Clin Pharmacokinet; 2010 Apr 27; 49(4):207-21. PubMed ID: 20214406
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase.
    Aouam K, Kolsi A, Kerkeni E, Ben Fredj N, Chaabane A, Monastiri K, Boughattas N.
    Pharmacogenomics; 2015 Dec 27; 16(18):2045-54. PubMed ID: 26615671
    [Abstract] [Full Text] [Related]

  • 17. Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation.
    Bouamar R, Hesselink DA, van Schaik RH, Weimar W, Macphee IA, de Fijter JW, van Gelder T.
    Ther Drug Monit; 2011 Apr 27; 33(2):178-84. PubMed ID: 21383650
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
    Quteineh L, Verstuyft C, Furlan V, Durrbach A, Letierce A, Ferlicot S, Taburet AM, Charpentier B, Becquemont L.
    Basic Clin Pharmacol Toxicol; 2008 Dec 27; 103(6):546-52. PubMed ID: 19067682
    [Abstract] [Full Text] [Related]

  • 20. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III).
    Yoon SH, Cho JH, Kwon O, Choi JY, Park SH, Kim YL, Yoon YR, Won DI, Kim CD.
    Transplantation; 2013 Mar 27; 95(6):828-34. PubMed ID: 23364483
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.